Bellevue Group AG lowered its holdings in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 34.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,055,796 shares of the medical research company's stock after selling 556,816 shares during the quarter. Bellevue Group AG owned 0.82% of NeoGenomics worth $17,400,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. SBI Securities Co. Ltd. bought a new stake in NeoGenomics during the fourth quarter worth about $26,000. Versant Capital Management Inc lifted its position in NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after buying an additional 1,142 shares in the last quarter. Sterling Capital Management LLC grew its holdings in NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock worth $61,000 after acquiring an additional 3,289 shares during the last quarter. Smartleaf Asset Management LLC increased its position in NeoGenomics by 203.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company's stock valued at $70,000 after acquiring an additional 2,787 shares in the last quarter. Finally, Blue Trust Inc. raised its stake in shares of NeoGenomics by 33.2% in the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after acquiring an additional 1,103 shares during the last quarter. Institutional investors own 98.50% of the company's stock.
NeoGenomics Stock Up 6.1 %
Shares of NeoGenomics stock opened at $7.70 on Friday. The firm has a market cap of $990.66 million, a PE ratio of -12.42 and a beta of 1.41. The business's 50 day simple moving average is $9.40 and its 200 day simple moving average is $13.26. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. NeoGenomics, Inc. has a 52-week low of $6.08 and a 52-week high of $19.12.
NeoGenomics (NASDAQ:NEO - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.06). NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. The business had revenue of $168.04 million during the quarter, compared to analyst estimates of $171.38 million. During the same quarter last year, the business earned ($0.02) earnings per share. NeoGenomics's revenue for the quarter was up 7.6% on a year-over-year basis. On average, analysts predict that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have weighed in on NEO shares. Piper Sandler dropped their price objective on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Morgan Stanley lowered their price target on NeoGenomics from $17.00 to $10.00 and set an "equal weight" rating for the company in a research note on Thursday. The Goldman Sachs Group reduced their target price on NeoGenomics from $15.00 to $10.00 and set a "buy" rating on the stock in a report on Wednesday. Needham & Company LLC lowered their price target on NeoGenomics from $18.00 to $8.50 and set a "buy" rating for the company in a report on Tuesday, April 29th. Finally, Benchmark lowered NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th. Five research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $14.50.
View Our Latest Research Report on NeoGenomics
About NeoGenomics
(
Free Report)
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.
Featured Articles
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics, Inc. (NASDAQ:NEO - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NeoGenomics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeoGenomics wasn't on the list.
While NeoGenomics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
